Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results
Roche Holding AG's Q2 and 1H 2025 earnings will, initially, broadly please the market despite recent pipeline and commercial setbacks. The pharmaceuticals division delivered strong revenue growth, up 10% year-over-year to $24bn in 1H25. The diagnostics division revenues remained flat at $7bn, attributed to specific market factors in China by Roche.
Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript
Roche Holding AG (OTCQX:RHHBY) Virtual Hematology Investor Conference Call June 23, 2025 1:00 PM ET Company Participants Bruno Eschli - Head of Investor Relations Charles S. Fuchs - Global Head of Oncology & Hematology Drug Development—Genentech & Roche Daud Chaudry - Corporate Participant Conference Call Participants Colin Peter White - UBS Investment Bank, Research Division David Paul Evans - Kepler Cheuvreux, Research Division Justin Steven Barrie Smith - Sanford C.
Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue
Genentech and AbbVie noted that Venclexta failed to help treat patients with newly diagnosed higher-risk MDS; However, this drug has already been approved for several other hematological indications. The 2% increase in revenue growth of the oncology portfolio was thanks to HER2 franchise; Primarily driven by 47% conversion rate in 58 launch countries by Phesgo. The decision was made to advance anti-alpha-synuclein monoclonal antibody prasinezumab into phase 3 development; Time to confirmed motor progression endpoint more pronounced in patients who took the drug alongside levodopa therapy.
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.
Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures
The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting.
Roche's Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says
The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.
Roche moves antibiotic against superbug into Phase 3 of testing
Swiss drugmaker Roche said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious hospital infections into the third and last phase of testing on humans.
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US
Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.
Roche Holding AG (RHHBY) is a Great Momentum Stock: Should You Buy?
Does Roche Holding AG (RHHBY) have what it takes to be a top stock pick for momentum investors? Let's find out.
